The incidence of anemia increases with the stage of chronic kidney disease (CKD). Erythropoietin (EPO) deficiency is a common cause of anemia in CKD. Erythropoietin-stimulating agents (ESAs) are the mainstay of the treatment. Treatment can be challenging due to erythropoietin resistance (ER), which can be assessed using the erythropoietin resistance index (ERI). Our aim was to investigate the factors contributing to high ERI levels in children receiving renal replacement therapy (RRT). Thirty-three children receiving RRT for at least 3 months were included. The mean ERI value was 15.7 IU/kg/w/g/dL. A significant association was observed between serum phosphorus levels and ERI (P = .016, r = 0.41). The mean parathormone (PTH) level was also higher in the high ERI group (599 ± 351 vs 392 ± 320 pg/mL, P = .088). An association, approaching statistical significance, was found between ERI and hypertension (P = .06, r = 0.32). Our study indicated a potential relationship between hyperphosphatemia, possibly secondary hyperparathyroidism, and ERI in children undergoing RRT.
AtkinsonMAMartzKWaradyBANeuAM.Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS. Pediatr Nephrol. 2010;25(9):1699-1706. doi:10.1007/s00467-010-1538-6.
2.
StaplesAOWongCSSmithJM, et al. Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(1):48-56. doi:10.2215/CJN.05301107.
3.
AtkinsonMAWaradyBA.Anemia in chronic kidney disease. Pediatr Nephrol. 2018;33(2):227-238. doi:10.1007/s00467-017-3663-y.
4.
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279-335.
5.
HayashiTJokiNTanakaY, et al. Resistance to erythropoiesis-stimulating agents in pre-dialysis and post-dialysis mortality in Japanese incident hemodialysis patients. Blood Purif. 2019;47(suppl 1):31-37. doi:10.1159/000496634.
6.
KatoHNangakuMHirakataH, et al. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial). Clin Exp Nephrol. 2018;22(1):78-84. doi:10.1007/s10157-017-1427-4.
7.
LuXZhangJWangSYuQLiH.High erythropoiesis resistance index is a significant predictor of cardiovascular and all-cause mortality in Chinese maintenance hemodialysis patients. Mediators Inflamm. 2020;2020(1):1-7. doi:10.1155/2020/1027230.
8.
PınarbaşıASDursunIGünayN, et al. Erythropoietin resistance index and the affecting factors in children with peritoneal dialysis. Blood Purif. 2021;50(6):942-951. doi:10.1159/000514060.
9.
MoisslUMWabelPChamneyPW, et al. Body fluid volume determination via body composition spectroscopy in health and disease. Physiol Meas. 2006;27(9):921-933. doi:10.1088/0967-3334/27/9/012.
10.
DiskinCJStokesTJDansbyLMRadcliffLCarterTB.Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients. Nephrology (Carlton). 2006;11(5):394-399. doi:10.1111/j.1440-1797.2006.00674.x.
11.
MehtaRCaiXHodakowskiA, et al. Fibroblast growth factor 23 and anemia in the chronic renal insufficiency cohort study. Clin J Am Soc Nephrol. 2017;12(11):1795-1803. doi:10.2215/CJN.03950417.
12.
WeirMR.Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents. Am J Nephrol. 2021;52(6):450-466. doi:10.1159/000516901.
13.
TanakaMKomabaHFukagawaM.Emerging association between parathyroid hormone and anemia in hemodialysis patients. Ther Apher Dial. 2018;22(3):242-245. doi:10.1111/1744-9987.12685.
14.
CzayaBHeitmanKCamposI, et al. Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling. Elife. 2022;11:e74782. doi:10.7554/eLife.74782.
15.
BoyleSMBernsJS.Erythropoietin and resistant hypertension in CKD. Semin Nephrol. 2014;34(5):540-549. doi:10.1016/j.semnephrol.2014.08.008.
16.
LeeMSLeeJSLeeJY.Prevention of erythropoietin-associated hypertension. Hypertension. 2007;50(2):439-445. doi:10.1161/HYPERTENSIONAHA.107.090423.
17.
TakahashiKTotsuneKImaiY, et al. Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. Clin Sci (Lond). 1993;84(1):47-50. doi:10.1042/cs0840047.
18.
RuschitzkaFTWengerRHStallmachT, et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci U S A. 2000;97(21):11609-11613. doi:10.1073/pnas.97.21.11609.
19.
VaziriNDZhouXJ.Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant. 2009;24(4):1082-1088. doi:10.1093/ndt/gfn601.
20.
CarliniRGDussoASObialoCIAlvarezUMRothsteinM.Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int. 1993;43(5):1010-1014. doi:10.1038/ki.1993.142.
21.
QureshiIZAbidKAmbreenFQureshiAL.Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure. Saudi Med J. 2007;28(2):193-196.
22.
HatanoMYoshidaTMimuroT, et al. The effects of ACE inhibitor treatment and ACE gene polymorphism on erythropoiesis in chronic hemodialysis patients. Nihon Jinzo Gakkai Shi. 2000;42(8):632-639. (In Japanese)
23.
MacdougallIC. Darbepoetin alfa: a new therapeutic agent for renal anemia. Kidney Int Suppl. 2002(80):55-61. doi:10.1046/j.1523-1755.61.s80.11.x.
24.
ArrietaJMoinaIMolinaJ, et al. Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability. Int J Nephrol Renovasc Dis. 2014;7:353-359. doi:10.2147/IJNRD.S61895.
25.
De PaepeMBSchelstraeteKHRingoirSMLameireNH.Influence of continuous ambulatory peritoneal dialysis on the anemia of endstage renal disease. Kidney Int. 1983;23(5):744-748.
26.
CoronelFHerreroJAMontenegroJ, et al. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis. J Nephrol. 2003;16(5):697-702.
27.
SuttorpMMHoekstraTRotmansJI, et al. Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients. BMC Nephrol. 2013;14:200. doi:10.1186/1471-2369-14-200.
28.
DuongUKalantar-ZadehKMolnarMZ, et al. Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients. Am J Nephrol. 2012;35(2):198-208. doi:10.1159/000335685.
29.
KanekoSHiraiKMorinoJ, et al. Association between carnitine deficiency and the erythropoietin resistance index in patients undergoing peritoneal dialysis: a cross-sectional observational study. Ren Fail. 2020;42(1):146-153. doi:10.1080/0886022X.2020.1719847.
30.
KimIYKimJHKimMJ, et al. Low 1,25-dihydroxyvitamin D level is associated with erythropoietin deficiency and endogenous erythropoietin resistance in patients with chronic kidney disease. Int Urol Nephrol. 2018;50(12):2255-2260. doi:10.1007/s11255-018-1967-x.
31.
ObiYMikamiSHamanoT, et al. Intravenous Vitamin B6 increases resistance to erythropoiesis-stimulating agents in hemodialysis patients: a randomized controlled trial. J Ren Nutr. 2019;26(6):380-390. doi:10.1053/j.jrn.2016.06.004.
32.
Bin SalehFSNajiMNEltayebAAHejailiFFAl SayyariAA.Effect of thyroid function status in hemodialysis patients on erythropoietin resistance and interdialytic weight gain. Saudi J Kidney Dis Transpl. 2018;29(6):1274-1279. doi:10.4103/1319-2442.248310.
33.
Joksimovic JovicJAnticSNikolicT, et al. Erythropoietin resistance development in hemodialysis patients: the role of oxidative stress. Oxid Med Cell Longev. 2022;2022(1):1-10. doi:10.1155/2022/9598211.
34.
FeretWSafranowKCiechanowskiKKwiatkowskaE.How is body composition and nutrition status associated with erythropoietin response in hemodialyzed patients? A single-center prospective cohort study. J Clin Med. 2022;11(9):2426. doi:10.3390/jcm11092426.
35.
HaraAKoshinoYKurokawaY, et al. Relationship between anti-erythropoietin receptor autoantibodies and responsiveness to erythropoiesis-stimulating agents in patients on hemodialysis: a multi-center cross-sectional study. Clin Exp Nephrol. 2020;24(1):88-95. doi:10.1007/s10157-019-01787-6.
36.
FujimotoDAdachiMMiyasatoY, et al. Efficacy of continuous erythropoietin receptor activator for end-stage renal disease patients with renal anemia before and after peritoneal dialysis initiation. Clin Exp Nephrol. 2021;25(2):191-199. doi:10.1007/s10157-020-01973-x.
37.
KaoCCWongHSWangYJ, et al. The role of genetic polymorphisms in STIM1 and ORAI1 for erythropoietin resistance in patients with renal failure. Medicine. 2021;100(17):e25243. doi:10.1097/MD.0000000000025243.
38.
RytaAChmielewskiMDebska-SlizienAJagodzinskiPSikorska-WisniewskaMLichodziejewska-NiemierkoM.Impact of gender and dialysis adequacy on anaemia in peritoneal dialysis. Int Urol Nephrol. 2017;49(5):903-908. doi:10.1007/s11255-016-1499-1.
